Home > Insider Trading > Filing (0001445866-16-002306)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
768408	Cyanotech Corp	CYAN	Medicinal Chemicals & Botanical Products (2833)	911206026

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1311443	Blueline Partners, L.l.c.	3480 Buskirk Avenue Suite 214 Pleasant Hill CA 94523	No	No	Yes	No
1460781	Blueline Capital Partners Ii, L.p.	3480 Buskirk Avenue Suite 214 Pleasant Hill CA 94523	No	No	Yes	No
1601397	Meridian Ohc Partners, Lp	425 Weed Street New Canaan CT 06840	No	No	Yes	No
1601536	Meridian Tsv Ii, Lp	425 Weed Street New Canaan CT 06840	No	No	Yes	No
1603326	Tsv Investment Partners, Llc	425 Weed Street New Canaan CT 06840	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-04-27	7,000	$5.20	741,395	No	4	P	Direct
Common Stock	Acquisiton	2016-04-27	305	$5.17	741,700	No	4	P	Direct
Common Stock	Acquisiton	2016-04-28	7,910	$5.21	749,610	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

These securities are owned by Meridian OHC Partners, LP. The price reported in Column 4 is a weighted average price. These shares reported herein were purchased in multiple transactions. The reporting persons undertake to provide to Cyanotech Corporation, any security holder of Cyanotech Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
As described in the Schedule 13D filing made on May 9, 2016 with respect to the Common Stock owned by Meridian OHC Partners, LP, Meridian TSV II, LP, TSV Investment Partners, LLC, BlueLine Capital Partners II, L.P. and BlueLine Partners, L.L.C., the Reporting Entities may have been deemed to be a "group" under Section 13(d) of the Securities Exchange Act and accordingly each Reporting Person may have been deemed to have beneficial ownership of 10% or more of the Common Stock.